ArticleJournal of arrhythmia2026
Early Versus Later Anticoagulation for Acute Ischemic Stroke in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
Article in Journal of arrhythmia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The optimal timing for initiating oral anticoagulation in patients with atrial fibrillation after acute ischemic stroke remains uncertain. This systematic review and meta-analysis aims to compare early versus later initiation of oral anticoagulants in this patient population. Methods: We systematically searched multiple databases, including MEDLINE, Embase, CENTRAL, and ClinicalTrials.gov, up to January 2026. We included randomized controlled trials (RCTs) comparing early (≤ 4 days, post-stroke) versus later (> 5 days) direct oral anticoagulation (DOAC) initiation in patients with atrial fibrillation and acute ischemic stroke. Our main outcomes were a primary composite outcome of ischemic stroke, sICH, or unclassified stroke and the primary composite outcome, or all-cause mortality. Results: Four RCTs were included with a total of 6722 patients. Our meta-analysis revealed no significant difference between early and later DOAC initiation for the primary composite outcome (RR: 0.84, 95% CI: 0.64-1.10), primary composite outcome or mortality (RR: 0.99; 95% CI: 0.82-1.19), ischemic stroke (RR: 0.78, 95% CI: 0.54-1.12), symptomatic intracranial hemorrhage (RR: 1.00, 95% CI: 0.48-2.06), all-cause mortality (RR: 0.96, 95% CI: 0.80-1.14), or major bleeding (RR: 0.72, 95% CI: 0.33-1.60). Conclusion: Early initiation of anticoagulants appears to be comparable to later initiation in terms of stroke recurrence, bleeding risks, and mortality in patients with atrial fibrillation. These findings support a more individualized approach to anticoagulation timing, balancing ischemic and hemorrhagic risks based on patient characteristics. Further high-quality trials are needed to refine clinical guidelines and optimize anticoagulation strategies in this population. Trial Registration: CRD42024629570 [PROSPERO].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.